4.8 Article

Specific Binding of Adamantane Drugs and Direction of Their Polar Amines in the Pore of the Influenza M2 Transmembrane Domain in Lipid Bilayers and Dodecylphosphocholine Micelles Determined by NMR Spectroscopy

期刊

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
卷 133, 期 12, 页码 4274-4284

出版社

AMER CHEMICAL SOC
DOI: 10.1021/ja102581n

关键词

-

资金

  1. NIH [GM088204, GM56423, AI74571]

向作者/读者索取更多资源

The transmembrane domain of the influenza M2 protein (M2TM) forms a tetrameric proton channel important for the virus lifecycle. The proton-channel activity is inhibited by amine-containing adamantyl drugs amantadine and rimantadine, which have been shown to bind specifically to the pore of M2TM near Ser31. However, whether the polar amine points to the N- or C-terminus of the channel has not yet been determined. Elucidating the polar group direction will shed light on the mechanism by which drug binding inhibits this proton channel and will facilitate rational design of new inhibitors. In this study, we determine the polar amine direction using M2TM reconstituted in lipid bilayers as well as dodecylphosphocholine (D PC) micelles. C-13-H-2 rotational-echo double-resonance NMR experiments of C-13-labeled M2TM and methyl-deuterated rimantadine in lipid bilayers showed that the polar amine pointed to the C-terminus of the channel, with the methyl group close to Gly34. Solution NMR experiments of M2TM in DPC micelles indicate that drug binding causes significant chemical shift perturbations of the protein that are very similar to those seen for M2TM and M2(18-60) bound to lipid bilayers. Specific H-2-labeling of the drugs permitted the assignment of drug-protein cross peaks, which indicate that amantadine and rimantadine bind to the pore in the same fashion as for bilayer-bound M2TM. These results strongly suggest that adamantyl inhibition of M2TM is achieved not only by direct physical occlusion of the channel, but also by perturbing the equilibrium constant of the proton-sensing residue His37. The reproduction of the pharmacologically relevant specific pore-binding site in DPC micelles, which was not observed with a different detergent, DHPC, underscores the significant influence of the detergent environment on the functional structure of this membrane protein.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Naoya Kitamura, Michael Dominic Sacco, Chunlong Ma, Yanmei Hu, Julia Alma Townsend, Xiangzhi Meng, Fushun Zhang, Xiujun Zhang, Mandy Ba, Tommy Szeto, Adis Kukuljac, Michael Thomas Marty, David Schultz, Sara Cherry, Yan Xiang, Yu Chen, Jun Wang

Summary: This study discovered 23R, one of the most potent and selective noncovalent SARS-CoV-2 MPpro inhibitors reported to date, and a novel binding pocket in MPpro that can be explored for inhibitor design.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Review Pharmacology & Pharmacy

Enterovirus A71 antivirals: Past, present, and future

Jun Wang, Yanmei Hu, Madeleine Zheng

Summary: Enterovirus A71 (EV-A71) is a significant human pathogen that particularly affects children. Existing vaccines for EV-A71 have limited protection and reduced efficacy against emerging strains. No approved antiviral for EV-A71 is currently available. Researchers have made progress in developing antivirals by targeting viral proteins and host factors, although some approaches have shown limited efficacy or side effects.

ACTA PHARMACEUTICA SINICA B (2022)

Article Virology

Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell

Yanmei Hu, Hyunil Jo, William F. DeGrado, Jun Wang

Summary: This study discovered the antiviral mechanism of Brilacidin, which inhibits the entry of multiple human coronaviruses by targeting HSPGs on the host cell surface. The study also found a strong synergistic effect of Brilacidin in combination with remdesivir against a specific coronavirus.

JOURNAL OF MEDICAL VIROLOGY (2022)

Article Pharmacology & Pharmacy

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

Chunlong Ma, Haozhou Tan, Juliana Choza, Yuyin Wang, Jun Wang

Summary: This study systematically characterizes the target specificity of Mpro inhibitors for COVID-19 and highlights the need for stringent hit validation in early-stage drug discovery.

ACTA PHARMACEUTICA SINICA B (2022)

Article Biochemistry & Molecular Biology

AG1478 Elicits a Novel Anti-Influenza Function via an EGFR-Independent, GBF1-Dependent Pathway

Xu Zhou, Lingxiang Zhu, Cheryl Bondy, Jun Wang, Qianwen Luo, Yin Chen

Summary: Current options for preventing or treating influenza are limited. However, a new study has discovered that a small molecule inhibitor called AG1478 has potent antiviral activity against influenza. The inhibitor targets the Golgi-specific GBF1-ARF1 system, rather than the EGFR inhibitory activity or interferon. This discovery highlights the potential of targeting host factors like GBF1 for developing effective treatments against influenza.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Chemistry, Medicinal

Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease

Haozhou Tan, Yanmei Hu, Prakash Jadhav, Bin Tan, Jun Wang

Summary: This article summarizes the significant progress in structure-based design and high-throughput screening of SARS-CoV-2 papain-like protease (PLpro) inhibitors since the beginning of the pandemic. Encouraging achievements include the development of non-covalent and covalent inhibitors with favorable pharmacokinetic properties. The article also identifies knowledge gaps that need to be addressed to advance PLpro inhibitors to clinical application.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor

Haozhou Tan, Chunlong Ma, Jun Wang

Summary: The COVID-19 pandemic has led to a significant interest in antiviral drug discovery. Recent studies have identified two natural compounds, dieckol and PGG, as potential SARS-CoV-2 M-pro inhibitors. However, further research has shown that neither compound inhibits M-pro, but PGG does inhibit SARS-CoV-2 PLpro. Unfortunately, PGG also exhibits cytotoxicity. Additionally, other compounds previously reported as SARS-CoV-2 PLpro inhibitors were found to be ineffective.

MEDICINAL CHEMISTRY RESEARCH (2022)

Article Chemistry, Medicinal

Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor

Chunlong Ma, Yanmei Hu, Yuyin Wang, Juliana Choza, Jun Wang

Summary: The global COVID-19 pandemic has highlighted the urgent need for effective antiviral drugs. This study focused on the development of inhibitors for the papain-like protease (PLpro), an important drug target due to its role in viral replication and host immune response. By screening a bioactive compound library, three compounds (EACC, KY-226, and tropifexor) were identified as potent PLpro inhibitors. Tropifexor, in particular, showed antiviral activity against SARS-CoV-2 in cells without causing cytotoxicity. These findings suggest that tropifexor has the potential to be further developed as an antiviral drug against SARS-CoV-2.

ACS INFECTIOUS DISEASES (2022)

Article Biochemistry & Molecular Biology

Stereospecific Effects of Benzimidazolonepiperidine Compounds on T-Type Ca2+ Channels and Pain

Kimberly Gomez, Cheng Tang, Bin Tan, Samantha Perez-Miller, Dongzhi Ran, Santiago Loya, Aida Calderon-Rivera, Harrison J. Stratton, Paz Duran, Kyleigh A. Masterson, Anna T. Gabrielsen, Omar Alsbiei, Angie Dorame, Maria Serafini, Aubin Moutal, Jun Wang, Rajesh Khanna

Summary: In this study, a library of compounds that inhibit T-type calcium channels was synthesized and screened, leading to the discovery of a novel blocker with in vivo efficacy against various types of pain.

ACS CHEMICAL NEUROSCIENCE (2022)

Article Chemistry, Medicinal

An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses

Jun Wang, Md Shahed-AI-Mahmud, Angelo Chen, Kan Li, Haozhou Tan, Ryan Joyce

Summary: The current monkeypox outbreaks during the COVID-19 pandemic have sparked renewed interest in antiviral drugs for orthopoxviruses. This perspective aims to summarize the antiviral activity, mechanism of action, and resistance mechanisms of orthopoxvirus antivirals to facilitate the development of additional drugs. The goal is to provide insights for medicinal chemists to prioritize drug targets and candidates for further development, thereby speeding up the discovery of orthopoxvirus antiviral drugs.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Virology

Telaprevir Treatment Reduces Paralysis in a Mouse Model of Enterovirus D68 Acute Flaccid Myelitis

Joshua Frost, Michael J. Rudy, J. Smith Leser, Haozhou Tan, Yanmei Hu, Jun Wang, Penny Clarke, Kenneth L. Tyler

Summary: Recent outbreaks of EV-D68 in 2014, 2016, and 2018 have led to over 600 cases of a paralytic illness called AFM. AFM primarily affects children, lacks an FDA-approved treatment, and shows limited recovery from limb weakness in many patients.

JOURNAL OF VIROLOGY (2023)

Article Biochemistry & Molecular Biology

Hexamethylene amiloride binds the SARS-CoV-2 envelope protein at the protein-lipid interface

Noah H. Somberg, Joao Medeiros-Silva, Hyunil Jo, Jun Wang, William F. Degrado, Mei Hong

Summary: This study used solid-state NMR to measure the binding distance between 5-(N,N-hexamethylene) amiloride (HMA) and the envelope protein (E) of SARS-CoV-2. The results showed that HMA binds to E with a stoichiometry of one drug per pentamer and is located on the lipid-facing surface of the protein. These findings provide insights into the inhibition mechanism of HMA for SARS-CoV-2 E.

PROTEIN SCIENCE (2023)

Letter Cell Biology

The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition

Michael Dominic Sacco, Yanmei Hu, Maura Verenice Gongora, Flora Meilleur, Michael Trent Kemp, Xiujun Zhang, Jun Wang, Yu Chen

CELL RESEARCH (2022)

Meeting Abstract Biophysics

Antiviral compounds investigated by solid-state deuterium NMR spectroscopy

Ankan Nath, Soohyun Lee, Trivikram R. Molugu, Jun Wang, Andrey V. Struts, Michael F. Brown

BIOPHYSICAL JOURNAL (2022)

Article Chemistry, Medicinal

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors

Chunlong Ma, Jun Wang

Summary: The study aimed to validate a range of compounds as SARS-CoV-2 PLpro inhibitors, but results showed that these compounds did not exhibit effective inhibition of PLpro at both enzymatic and cellular levels. Therefore, further efforts are needed to search for more potent and specific SARS-CoV-2 PLpro inhibitors.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

暂无数据